A mechanistic model of curative combination therapy explains lymphoma clinical trial results

Amy E. Pomeroy; Adam C. Palmer

doi:10.1101/2024.06.25.24309486

ABSTRACT

Combinations of chemotherapies are used to treat many cancer types as they elicit higher cure rates and longer responses than single drugs. Several rationales contribute to the efficacy of combinations, including overcoming inter-patient and intra-tumor heterogeneity and improving efficacy through additive or synergistic pharmacological effects. We present a quantitative model that unifies these phenomena to simulate the clinical activity of curative combination therapies. This mechanistic simulation describes kinetics of tumor growth and death in response to treatment and outputs progression-free survival (PFS) distributions in patient populations. We applied this model to first-line combination therapy for Diffuse Large B-Cell Lymphoma, which is cured in most patients by the 5-drug combination RCHOP. This mechanistic model reproduced clinically observed PFS distributions, kinetics of tumor killing measured by circulating tumor DNA, and the adverse prognostic effect of tumor proliferation rate. The outcomes of nine phase 3 trials of new therapies combined with RCHOP were accurately predicted by the model, based on new therapies’ efficacies in trials in patients with relapsed or refractory disease. Finally, we used the model to explore how drug synergy and predictive biomarkers affect the chance of success of randomized trials. These findings show that curative combination therapies can be understood in quantitative and kinetic detail, and that predictive simulations can be used to aid the design of new treatment regimens and clinical trials in curative-intent settings.

SIGNIFICANCE A novel model that incorporates pharmacological interactions in the presence of inter-patient and intra-tumor heterogeneity explains and predicts combination clinical trial outcomes of curative regimes used to treat Diffuse Large B-cell lymphoma. This model can be used to understand and inform optimal design of drug combinations and clinical trials.

Competing Interest Statement

A.C.P. has received consulting fees from AstraZeneca, Kymera, Merck, Novartis, and Sanofi, and research funding from Prelude Therapeutics. A.E.P. has received consulting fees from Respiratorious AB.

Funding Statement

The study was funded by NCI grant R01CA279968. A.E.P. is supported by NIGMS grant K12GM000678.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data used in the study are from previously published studies as cited in the manuscript.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.